RxDoctor Payments Data

Tonya Buchanan

Adult Health · Saint Louis, MONPI 1043556467

Payments from drug & device makers

$1,511in general payments, 2019–2025

Across 16 payments — averaging $94.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$269
  • Mallinckrodt Hospital Products Inc.$130
  • Neurocrine Biosciences, Inc.$125
  • GSK$123
  • Avanir Pharmaceuticals, Inc.$120
  • AbbVie$117
  • plus $628 from 7 others

What the payments were for

  • Food & beverage$1,511100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,511 in reported general payments places this provider in the 65th percentile of 555 adult health providers in Missouri.

See all adult health providers in Missouri

Medicare billing

Part B allowed, 2024
$10,292
Medicare patients
72
Services billed
178

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala18$78,365
OzempicSemaglutide56$68,755
JardianceEmpagliflozin53$68,379
EliquisApixaban49$54,349
TrulicityDulaglutide44$50,955
MounjaroTirzepatide21$30,522
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$26,598
EntrestoSacubitril/Valsartan19$23,167
XareltoRivaroxaban20$21,433
JanuviaSitagliptin Phosphate20$19,093
Breo ElliptaFluticasone/Vilanterol19$12,503
LinzessLinaclotide15$11,173
Albuterol Sulfate HfaAlbuterol Sulfate352$10,756
Fluticasone-SalmeterolFluticasone Propion/Salmeterol30$10,619
MyrbetriqMirabegron11$5,916

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$102$68,75556 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta$123$46,02268 claims
AbbVieLinzess$117$11,17315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 555 adult health providers in Missouri.

Other adult health in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →